<DOC>
	<DOCNO>NCT01853046</DOCNO>
	<brief_summary>To characterize pharmacokinetics safety regorafenib cancer subject severe renal impairment compare Control group ( cancer subject normal mildly impaired renal function )</brief_summary>
	<brief_title>Pharmacokinetics Safety Regorafenib ( BAY73-4506 ) Cancer Subjects With Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Subjects histologically confirm , locally advanced metastatic , refractory solid tumor candidate standard therapy Male female subject ≥ 18 year age Women childbearing potential must negative urine pregnancy test perform within 7 day start study treatment Life expectancy least 8 week Adequate bone marrow , liver function assess follow laboratory requirement conduct within 7 day start study treatment Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 For subject NORMAL OR MILDLY IMPAIRED RENAL FUNCTION ( Control group ) ; test within 7 day start study treatment : Estimated creatinine clearance ( CLcr ) ≥ 60 mL/min calculate use CockcroftGault equation For subject SEVERELY IMPAIRED renal function ; test within 7 day start study treatment : CLcr 1529 mL/min calculate use CockcroftGault equation Symptomatic metastatic brain meningeal tumor Major surgical procedure , open biopsy , significant traumatic injury within 28 day start study medication History organ allograft Nonhealing wound , skin ulcer , bone fracture Pheochromocytoma Uncontrolled concurrent medical illness include uncontrolled hypertension History cardiac disease Pleural effusion ascites cause respiratory compromise Interstitial lung disease ongoing sign symptoms time screen Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month start study medication Subjects evidence history bleed diathesis ; hemorrhage bleed event NCICTCAE Grade ≥ 3 high within 4 week start investigational treatment Dehydration NCICTCAEversion 4.0 Grade ≥ 1 Unresolved toxicity high NCICTCAE version 4.0 Grade 1 attribute prior therapy/procedure ( exclude alopecia anemia grade 2 neuropathy reversible due oxaliplatin ) Seizure disorder require anticonvulsant therapy ( steroids antiepileptic ) For subject SEVERELY IMPAIRED renal function : Renal failure require hemo peritoneal dialysis Acute renal failure Acute nephritis Nephrotic syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>severe renal impairment</keyword>
	<keyword>Solid tumor</keyword>
</DOC>